BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Skountzou I, Quan FS, Gangadhara S, Ye L, Vzorov A, Selvaraj P, Jacob J, Compans RW, Kang SM. Incorporation of glycosylphosphatidylinositol-anchored granulocyte- macrophage colony-stimulating factor or CD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles. J Virol 2007;81:1083-94. [PMID: 17108046 DOI: 10.1128/JVI.01692-06] [Cited by in Crossref: 58] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Ludwig C, Wagner R. Virus-like particles-universal molecular toolboxes. Curr Opin Biotechnol 2007;18:537-45. [PMID: 18083549 DOI: 10.1016/j.copbio.2007.10.013] [Cited by in Crossref: 197] [Cited by in F6Publishing: 181] [Article Influence: 14.1] [Reference Citation Analysis]
2 Zhang R, Zhang S, Li M, Chen C, Yao Q. Incorporation of CD40 ligand into SHIV virus-like particles (VLP) enhances SHIV-VLP-induced dendritic cell activation and boosts immune responses against HIV. Vaccine 2010;28:5114-27. [PMID: 20471443 DOI: 10.1016/j.vaccine.2010.03.079] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis]
3 Urban JH, Merten CA. Retroviral display in gene therapy, protein engineering, and vaccine development. ACS Chem Biol 2011;6:61-74. [PMID: 21171610 DOI: 10.1021/cb100285n] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
4 Vzorov AN, Uryvaev LV. Requirements for the Induction of Broadly Neutralizing Antibodies against HIV-1 by Vaccination. Mol Biol 2017;51:819-29. [DOI: 10.1134/s0026893317060176] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
5 Melchers M, Matthews K, de Vries RP, Eggink D, van Montfort T, Bontjer I, van de Sandt C, David K, Berkhout B, Moore JP, Sanders RW. A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells. Retrovirology 2011;8:48. [PMID: 21689404 DOI: 10.1186/1742-4690-8-48] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
6 Skountzou I, Martin Mdel P, Wang B, Ye L, Koutsonanos D, Weldon W, Jacob J, Compans RW. Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. Vaccine 2010;28:4103-12. [PMID: 19654062 DOI: 10.1016/j.vaccine.2009.07.058] [Cited by in Crossref: 77] [Cited by in F6Publishing: 75] [Article Influence: 5.9] [Reference Citation Analysis]
7 Liu SS, Liu YS, Guo XY, Murakami Y, Yang G, Gao XD, Kinoshita T, Fujita M. A knockout cell library of GPI biosynthetic genes for functional studies of GPI-anchored proteins. Commun Biol 2021;4:777. [PMID: 34162996 DOI: 10.1038/s42003-021-02337-1] [Reference Citation Analysis]
8 Patel JM, Kim MC, Vartabedian VF, Lee YN, He S, Song JM, Choi HJ, Yamanaka S, Amaram N, Lukacher A, Montemagno CD, Compans RW, Kang SM, Selvaraj P. Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses. Nanomedicine 2015;11:1097-107. [PMID: 25752855 DOI: 10.1016/j.nano.2015.02.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
9 Kushnir N, Streatfield SJ, Yusibov V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine. 2012;31:58-83. [PMID: 23142589 DOI: 10.1016/j.vaccine.2012.10.083] [Cited by in Crossref: 347] [Cited by in F6Publishing: 319] [Article Influence: 34.7] [Reference Citation Analysis]
10 Kang SM, Song JM, Quan FS, Compans RW. Influenza vaccines based on virus-like particles. Virus Res 2009;143:140-6. [PMID: 19374929 DOI: 10.1016/j.virusres.2009.04.005] [Cited by in Crossref: 107] [Cited by in F6Publishing: 97] [Article Influence: 8.2] [Reference Citation Analysis]
11 Qi Y, Kang H, Zheng X, Wang H, Gao Y, Yang S, Xia X. Incorporation of membrane-anchored flagellin or Escherichia coli heat-labile enterotoxin B subunit enhances the immunogenicity of rabies virus-like particles in mice and dogs. Front Microbiol 2015;6:169. [PMID: 25784906 DOI: 10.3389/fmicb.2015.00169] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
12 Wang BZ, Quan FS, Kang SM, Bozja J, Skountzou I, Compans RW. Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol 2008;82:11813-23. [PMID: 18786995 DOI: 10.1128/JVI.01076-08] [Cited by in Crossref: 99] [Cited by in F6Publishing: 68] [Article Influence: 7.1] [Reference Citation Analysis]
13 Quan FS, Steinhauer D, Huang C, Ross TM, Compans RW, Kang SM. A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine 2008;26:3352-61. [PMID: 18468740 DOI: 10.1016/j.vaccine.2008.03.055] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 4.6] [Reference Citation Analysis]
14 Metzner C, Kochan F, Dangerfield JA. Fluorescence molecular painting of enveloped viruses. Mol Biotechnol 2013;53:9-18. [PMID: 23104232 DOI: 10.1007/s12033-012-9616-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
15 Vassilieva EV, Kalluri H, McAllister D, Taherbhai MT, Esser ES, Pewin WP, Pulit-Penaloza JA, Prausnitz MR, Compans RW, Skountzou I. Improved immunogenicity of individual influenza vaccine components delivered with a novel dissolving microneedle patch stable at room temperature. Drug Deliv Transl Res 2015;5:360-71. [PMID: 25895053 DOI: 10.1007/s13346-015-0228-0] [Cited by in Crossref: 62] [Cited by in F6Publishing: 50] [Article Influence: 10.3] [Reference Citation Analysis]
16 Sun Y, Carrion R Jr, Ye L, Wen Z, Ro YT, Brasky K, Ticer AE, Schwegler EE, Patterson JL, Compans RW, Yang C. Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Virology 2009;383:12-21. [PMID: 18986663 DOI: 10.1016/j.virol.2008.09.020] [Cited by in Crossref: 73] [Cited by in F6Publishing: 67] [Article Influence: 5.2] [Reference Citation Analysis]
17 Koutsonanos DG, Vassilieva EV, Stavropoulou A, Zarnitsyn VG, Esser ES, Taherbhai MT, Prausnitz MR, Compans RW, Skountzou I. Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection. Sci Rep 2012;2:357. [PMID: 22500210 DOI: 10.1038/srep00357] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 7.6] [Reference Citation Analysis]
18 Rynda-Apple A, Patterson DP, Douglas T. Virus-like particles as antigenic nanomaterials for inducing protective immune responses in the lung. Nanomedicine (Lond) 2014;9:1857-68. [PMID: 25325241 DOI: 10.2217/nnm.14.107] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
19 Cheng LF, Wang F, Zhang L, Yu L, Ye W, Liu ZY, Ying QK, Wu XA, Xu ZK, Zhang FL. Incorporation of GM-CSF or CD40L Enhances the Immunogenicity of Hantaan Virus-Like Particles. Front Cell Infect Microbiol 2016;6:185. [PMID: 28066721 DOI: 10.3389/fcimb.2016.00185] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
20 Pritam M, Singh G, Kumar R, Singh SP. Screening of potential antigens from whole proteome and development of multi-epitope vaccine against Rhizopus delemar using immunoinformatics approaches. Journal of Biomolecular Structure and Dynamics. [DOI: 10.1080/07391102.2022.2028676] [Reference Citation Analysis]
21 Song JM, Wang BZ, Park KM, Van Rooijen N, Quan FS, Kim MC, Jin HT, Pekosz A, Compans RW, Kang SM. Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One 2011;6:e14538. [PMID: 21267073 DOI: 10.1371/journal.pone.0014538] [Cited by in Crossref: 90] [Cited by in F6Publishing: 88] [Article Influence: 8.2] [Reference Citation Analysis]
22 Mohan T, Kim J, Berman Z, Wang S, Compans RW, Wang BZ. Co-delivery of GPI-anchored CCL28 and influenza HA in chimeric virus-like particles induces cross-protective immunity against H3N2 viruses. J Control Release 2016;233:208-19. [PMID: 27178810 DOI: 10.1016/j.jconrel.2016.05.021] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
23 Sailaja G, Skountzou I, Quan FS, Compans RW, Kang SM. Human immunodeficiency virus-like particles activate multiple types of immune cells. Virology 2007;362:331-41. [PMID: 17276476 DOI: 10.1016/j.virol.2006.12.014] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 3.5] [Reference Citation Analysis]
24 Koutsonanos DG, del Pilar Martin M, Zarnitsyn VG, Sullivan SP, Compans RW, Prausnitz MR, Skountzou I. Transdermal influenza immunization with vaccine-coated microneedle arrays. PLoS One 2009;4:e4773. [PMID: 19274084 DOI: 10.1371/journal.pone.0004773] [Cited by in Crossref: 131] [Cited by in F6Publishing: 121] [Article Influence: 10.1] [Reference Citation Analysis]
25 Shirbaghaee Z, Bolhassani A. Different applications of virus-like particles in biology and medicine: Vaccination and delivery systems. Biopolymers 2016;105:113-32. [PMID: 26509554 DOI: 10.1002/bip.22759] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 9.2] [Reference Citation Analysis]
26 Huang D, Pereboev AV, Korokhov N, He R, Larocque L, Gravel C, Jaentschke B, Tocchi M, Casley WL, Lemieux M, Curiel DT, Chen W, Li X. Significant alterations of biodistribution and immune responses in Balb/c mice administered with adenovirus targeted to CD40(+) cells. Gene Ther 2008;15:298-308. [PMID: 18046426 DOI: 10.1038/sj.gt.3303085] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
27 Feng H, Zhang H, Deng J, Wang L, He Y, Wang S, Seyedtabaei R, Wang Q, Liu L, Galipeau J, Compans RW, Wang BZ. Incorporation of a GPI-anchored engineered cytokine as a molecular adjuvant enhances the immunogenicity of HIV VLPs. Sci Rep 2015;5:11856. [PMID: 26150163 DOI: 10.1038/srep11856] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
28 Creytens S, Pascha MN, Ballegeer M, Saelens X, de Haan CAM. Influenza Neuraminidase Characteristics and Potential as a Vaccine Target. Front Immunol 2021;12:786617. [PMID: 34868073 DOI: 10.3389/fimmu.2021.786617] [Reference Citation Analysis]
29 Lin FC, Peng Y, Jones LA, Verardi PH, Yilma TD. Incorporation of CD40 ligand into the envelope of pseudotyped single-cycle Simian immunodeficiency viruses enhances immunogenicity. J Virol 2009;83:1216-27. [PMID: 19036823 DOI: 10.1128/JVI.01870-08] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
30 Kang SM, Kim MC, Compans RW. Virus-like particles as universal influenza vaccines. Expert Rev Vaccines 2012;11:995-1007. [PMID: 23002980 DOI: 10.1586/erv.12.70] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 6.0] [Reference Citation Analysis]
31 Wang S, Liu H, Zhang X, Qian F. Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies. Protein Cell 2015;6:480-503. [PMID: 25944045 DOI: 10.1007/s13238-015-0164-2] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 9.0] [Reference Citation Analysis]
32 Heider S, Dangerfield JA, Metzner C. Biomedical applications of glycosylphosphatidylinositol-anchored proteins. J Lipid Res 2016;57:1778-88. [PMID: 27542385 DOI: 10.1194/jlr.R070201] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]